Join us on Wednesday, 24th September at 10:00 AM AEST for a live webinar featuring Radiopharm Theranostics Limited (ASX:RAD), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need. 

Radiopharm is advancing a diversified pipeline with several clinical-stage programs across multiple cancer indications — and another program expected to begin by year’s end. Its platform spans peptides, small molecules and monoclonal antibodies, targeting hard-to-treat cancers such as lung, breast and brain metastases. 

Recent milestones include:
•    US FDA IND clearance for its first-in-human Phase 1 trial of Betabart (RV-01), a monoclonal antibody developed with MD Anderson Cancer Center
•    US FDA Fast Track Designation for RAD101, a novel imaging agent for brain metastases

Hear directly from Managing Director and CEO Riccardo Canevari as he shares clinical strategy insights, pipeline progress and how Radiopharm is reshaping the oncology landscape.
Don’t miss this opportunity to engage with a radiopharma innovator at the forefront of precision oncology.

Register now to secure your spot!